Preview

Российский журнал детской гематологии и онкологии (РЖДГиО)

Расширенный поиск

Клинический обзор анти-CD19 BiTE® и ex vivo данных об анти-CD33 BiTE® в качестве примеров ретаргетирования Т-клеток при гематологических опухолях

https://doi.org/10.17650/2311-1267-2016-3-2-18-30

Полный текст:

Аннотация

Блинатумомаб – биспецифичное антитело, созданное для воздействия на CD-19 клетки, является наиболее продвинутой частью биспецифических молекул, рекрутеров Т-клеток (BiTE®). Программа клинических исследований препарата включает такие нозологии, как В-клеточный острый лимфобластный лейкоз (ОЛЛ) и В-клеточную неходжкинскую лимфому (НХЛ). Достижения ремиссии удалось достичь как у взрослых, так и у детей с рефрактерным/рецидивирующим течением В-клеточного ОЛЛ, что позволило успешно выполнить аллогенную трансплантацию гемопоэтических стволовых клеток. Также блинатумомаб обладал стойким ответом к В-клеточной вялотекущей НХЛ. Блинатумомаб недавно получил одобрение FDA (США) для лечения рефрактерного/рецидивирующего ОЛЛ из клеток предшественников В-лимфоцитов, отрицательного по филадельфийской хромосоме. AMG 330 является исследовательским анти-CD33 BiTE®-антителом. Тестирование в режиме ex vivo на первичных образцах CD33-позитивных пациентов с острым миелоидным лейкозом показало экспансию и цитотоксический эффект против злокачественных клеток у AMG 330. 

Оригинальная статья “Clinical overview of anti-CD19 BiTE® and ex vivo data from anti-CD33 BiTE® as examples for retargeting T cells in hematologic malignancies” опубликована в журнале Mol Immunol 2015;67(2 Pt A):58–66. doi: 10.1016/j.molimm.2015.02.033. Epub 2015 Apr 13. Стиль и оформле- ние статьи сохранены. Все права защищены. © 2015 Elsevier Ltd.

Об авторах

Г. Зугмайер
Институт исследований Amgen, Мюнхен
Германия


М. Клингер
Институт исследований Amgen, Мюнхен
Германия


М. Шмидт
Институт исследований Amgen, Мюнхен
Германия


М. Субклеве
Департамент внутренней медицины III, Мюнхенский университет, Мюнхен; Клиническое сотрудничество Группа иммунотерапии, Институт им. Гельмгольца, Мюнхен, Германия
Германия


К. И. Киргизов

Россия
Автор перевода


Т. В. Шаманская

Россия
Автор перевода


Список литературы

1. Aigner, M., Feulner, J., Schaffer, S., Kischel, R., Kufer, P., Schneider, K., Henn, A., Rattel, B., Friedrich, M., Baeuerle, P.A., Mackensen, A., Krause, S.W., 2013. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 27, 1107–1115.

2. Bader, P., Kreyenberg, H., Henze, G.H.R., Eckert, C., Reising, M., Willasch, A., Barth, A., Borkhardt, A., Peters, C., Handgretinger, R., Sykora, K.-W., Holter, W., Kabisch, H., Klingebiel, T., von Stackelberg, A., 2009. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J. Clin. Oncol. 27, 377–384.

3. Baessler, T., Charton, J.E., Schmiedel, B.J., Grunebach, F., Krusch, M., Wacker, A., Rammensee, H.G., Salih, H.R., 2010. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK￾cell reactivity against human acute myeloid leukemia cells. Blood 115, 3058–3069.

4. Baessler, T., Krusch, M., Schmiedel, B.J., Kloss, M., Baltz, K.M., Wacker, A., Schmetzer, H.M., Salih, H.R., 2009. Glucocorticoid-induced tumor necrosis factor receptor- related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res. 69, 1037–1045.

5. Baeuerle, P.A., Kufer, P., Bargou, R., 2009. BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr. Opin. Mol. Ther. 11, 22–30.

6. Baeuerle, P.A., Reinhardt, C., Kufer, P., 2008. BiTE: a new class of antibodies that recruit T-cells. Drugs Future 33, 137.

7. Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., Einsele, H., Brandl, C., Wolf, A., Kirchinger, P., Klappers, P., Schmidt, M., Riethmuller, G., Reinhardt, C., Baeuerle, P.A., Kufer, P., 2008. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974–977.

8. Bassan, R., Spinelli, O., Oldani, E., Intermesoli, T., Tosi, M., Peruta, B., Rossi, G., Borlenghi, E., Pogliani, E.M., Terruzzi, E., Fabris, P., Cassibba, V., Lambertenghi-Deliliers, G., Cortelezzi, A., Bosi, A., Gianfaldoni, G., Ciceri, F., Bernardi, M., Gallamini, A., Mattei, D., Di Bona, E., Romani, C., Scattolin, A.M., Barbui, T., Rambaldi, A., 2009. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 113, 4153–4162.

9. Borowitz, M.J., Devidas, M., Hunger, S.P., Bowman, W.P., Carroll, A.J., Carroll, W.L., Linda, S., Martin, P.L., Pullen, D.J., Viswanatha, D., Willman, C.L., Winick, N., Camitta, B.M., Children’s Oncology Group, 2008. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood 111, 5477–5485.

10. Brandl, C., Haas, C., d’Argouges, S., Fisch, T., Kufer, P., Brischwein, K., Prang, N., Bargou, R., Suzich, J., Baeuerle, P.A., Hofmeister, R., 2007. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific singlechain antibody construct. Cancer Immunol. Immunother. 56, 1551–1563.

11. Brischwein, K., Parr, L., Pflanz, S., Volkland, J., Lumsden, J., Klinger, M., Locher, M., Hammond, S.A., Kiener, P., Kufer, P., Schlereth, B., Baeuerle, P.A., 2007. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J. Immunother. 30, 798–807.

12. Bross, P.F., Beitz, J., Chen, G., Chen, X.H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., Williams, G., Pazdur, R., 2001. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7, 1490–1496.

13. Bruggemann, M., Raff, T., Flohr, T., Gö kbuget, N., Nakao, M., Droese, J., Luschen, S., Pott, C., Ritgen, M., Scheuring, U., Horst, H.A., Thiel, E., Hoelzer, D., Bartram, C.R., Kneba, M., 2006. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 107, 1116– 1123.

14. Burnett, A., Wetzler, M., Lowenberg, B., 2011. Therapeutic advances in acute myeloid leukemia. J. Clin. Oncol. 29, 487–494.

15. Coles, S.J., Wang, E.C., Man, S., Hills, R.K., Burnett, A.K., Tonks, A., Darley, R.L., 2011. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 25, 792–799.

16. Conter, V., Bartram, C.R., Valsecchi, M.G., Schrauder, A., Panzer-Grumayer, R., Moricke, A., Arico, M., Zimmermann, M., Mann, G., De Rossi, G., Stanulla, M., Locatelli, F., Basso, G., Niggli, F., Barisone, E., Henze, G., Ludwig, W.D., Haas, O.A., Cazzaniga, G., Koehler, R., Silvestri, D., Bradtke, J., Parasole, R., Beier, R., van Dongen, J.J., Biondi, A., Schrappe, M., 2010. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115, 3206–3214.

17. DeWeerdt, S., 2014. Bakterien gegen Tumoren. Spek. Wissensch. 7, 30–34.

18. Dreier, T., Baeuerle, P.A., Fichtner, I., Grun, M., Schlereth, B., Lorenczewski, G., Kufer, P., Lutterbuse, R., Riethmuller, G., Gjorstrup, P., Bargou, R.C., 2003. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19−/CD3− bispecific single-chain antibody construct. J. Immunol. 170, 4397–4402.

19. Dreier, T., Lorenczewski, G., Brandl, C., Hoffmann, P., Syring, U., Hanakam, F., Kufer, P., Riethmuller, G., Bargou, R., Baeuerle, P.A., 2002. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int. J. Cancer 100, 690–697.

20. Dudley, M.E., Wunderlich, J.R., Yang, J.C., Sherry, R.M., Topalian, S.L., Restifo, N.P., Royal, R.E., Kammula, U., White, D.E., Mavroukakis, S.A., Rogers, L.J., Gracia, G.J., Jones, S.A., Mangiameli, D.P., Pelletier, M.M., Gea-Banacloche, J., Robinson, M.R., Berman, D.M., Filie, A.C., Abati, A., Rosenberg, S.A., 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346–2357.

21. Feldman, E.J., Brandwein, J., Stone, R., Kalaycio, M., Moore, J., O’Connor, J., Wedel, N., Roboz, G.J., Miller, C., Chopra, R., Jurcic, J.C., Brown, R., Ehmann, W.C., Schulman,P., Frankel, S.R., De Angelo, D., Scheinberg, D., 2005. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J. Clin. Oncol. 23, 4110–4116.

22. Frankel, S.R., Baeuerle, P.A., 2013. Targeting T cells to tumor cells using bispecific antibodies. Curr. Opin. Chem. Biol. 17, 385–392. Garber, K., 2014. Bispecific antibodies rise again. Nat. Rev. Drug Discov. 13, 799–801.

23. Gö kbuget, N., Kneba, M., Raff, T., Trautmann, H., Bartram, C.R., Arnold, R., Fietkau, R., Freund, M., Ganser, A., Ludwig, W.D., Maschmeyer, G., Rieder, H., Schwartz, S., Serve, H., Thiel, E., Bruggemann, M., Hoelzer, D., German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia, 2012. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 120, 1868–1876.

24. Haas, C., Krinner, E., Brischwein, K., Hoffmann, P., Lutterbuse, R., Schlereth, B., Kufer, P., Baeuerle, P.A., 2009. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 214, 441–453.

25. Handgretinger, R., Zugmaier, G., Henze, G., Kreyenberg, H., Lang, P., von Stackelberg, A., 2011. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 25, 181–184.

26. Hijazi, Y., Klinger, M., Schub, A., Wu, B., Zhu, M., Kufer, P., Wolf, A., Nagorsen, D., 2013. Blinatumomab exposure and pharmacodynamic response in patients with non-Hodgkin lymphoma (NHL). J. Clin. Oncol. 31 (abstr), 3051.

27. Hoffmann, P., Hofmeister, R., Brischwein, K., Brandl, C., Crommer, S., Bargou, R., Itin, C., Prang, N., Baeuerle, P.A., 2005. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19−/CD3− bispecific single-chain antibody construct. Int. J. Cancer 115, 98–104.

28. Hubmann, M., Kohnke, T., Hoster, E., Schneider, S., Dufour, A., Zellmeier, E., Fiegl, M., Braess, J., Bohlander, S.K., Subklewe, M., Sauerland, M.C., Berdel, W.E., Buchner, T., Wormann, B., Hiddemann, W., Spiekermann, K., 2014. Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse. Haematologica 99, 1317–1325.

29. Jedema, I., Barge, R.M., van der Velden, V.H., Nijmeijer, B.A., van Dongen, J.J., Willemze, R., Falkenburg, J.H., 2004. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33- negative malignancies with endocytic capacity. Leukemia 18, 316–325.

30. Klinger, M., Brandl, C., Zugmaier, G., Hijazi, Y., Bargou, R.C., Topp, M.S., Gö kbuget, N., Neumann, S., Goebeler, M., Viardot, A., Stelljes, M., Bruggemann, M., Hoelzer, D., Degenhard, E., Nagorsen, D., Baeuerle, P.A., Wolf, A., Kufer, P., 2012. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119, 6226–6233.

31. Klinger, M., Kufer, P., Kirchinger, P., Lutterbuese, P., Leo, E., Reinhardt, C., Baeuerle, P.A., Bargou, R., 2006. T cell responses during long-term continuous infusion of MT103 (MEDI-538; anti-CD19 BiTE) in patients with relapsed B-NHL: data from dose-escalation study MT103-104. Blood (ASH Annu. Meet. Abstr.) 108, 2725 (abstract 903-II).

32. Klinger, M., Nagorsen, D., Brandl, C., Wissing, S., Meier, P., Baeuerle, P.A., Kufer, P., 2009. Pharmacodynamic analyses of peripheral blood from relapsed B-NHL patients treated with anti-CD19/-CD3 bispecific BiTE® antibody blinatumomab. Haematologica 94, 174–175.

33. Kohnke, T., Sauter, D., Ringel, K., Hoster, E., Laubender, R.P., Hubmann, M., Bohlander, S.K., Kakadia, P.M., Schneider, S., Dufour, A., Sauerland, M.C., Berdel, W.E., Buchner, T., Wormann, B., Braess, J., Hiddemann, W., Spiekermann, K., Subklewe, M., 2014. Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse. Leukemia 29, 377–386.

34. Krupka, C., Kufer, P., Kischel, R., Zugmaier, G., Bogeholz, J., Kohnke, T., Lichtenegger, F.S., Schneider, S., Metzeler, K.H., Fiegl, M., Spiekermann, K., Baeuerle, P.A., Hiddemann, W., Riethmuller, G., Subklewe, M., 2014. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cellengaging antibody AMG 330. Blood 123, 356–365.

35. Kung Sutherland, M.S., Walter, R.B., Jeffrey, S.C., Burke, P.J., Yu, C., Kostner, H., Stone, I., Ryan, M.C., Sussman, D., Lyon, R.P., Zeng, W., Harrington, K.H., Klussman, K., Westendorf, L., Meyer, D., Bernstein, I.D., Senter, P.D., Benjamin, D.R., Drachman, J.G., McEarchern, J.A., 2013. SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 122, 1455–1463.

36. Lichtenegger, F.S., Schnorfeil, F.M., Hiddemann, W., Subklewe, M., 2013. Current strategies in immunotherapy for acute myeloid leukemia. Immunotherapy 5, 63–78.

37. Lim, S.H., Vaughan, A.T., Ashton-Key, M., Williams, E.L., Dixon, S.V., Chan, H.T., Beers, S.A., French, R.R., Cox, K.L., Davies, A.J., Potter, K.N., Mockridge, C.I., Oscier, D.G., Johnson, P.W., Cragg, M.S., Glennie, M.J., 2011. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 118, 2530–2540.

38. Lion, E., Willemen, Y., Berneman, Z.N., Van Tendeloo, V.F., Smits, E.L., 2012. Natural killer cell immune escape in acute myeloid leukemia. Leukemia 26, 2019–2026.

39. Loffler, A., Kufer, P., Lutterbuse, R., Zettl, F., Daniel, P.T., Schwenkenbecher, J.M., Riethmuller, G., Dorken, B., Bargou, R.C., 2000. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95, 2098–2103.

40. Lu, H., Zhou, Q., Deshmukh, V., Phull, H., Ma, J., Tardif, V., Naik, R.R., Bouvard, C., Zhang, Y., Choi, S., Lawson, B.R., Zhu, S., Kim, C.H., Schultz, P.G., 2014. Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia. Angew. Chem. Int. Ed. Engl. 53, 9841–9845.

41. Mack, M., Riethmuller, G., Kufer, P., 1995. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl. Acad. Sci. U. S. A. 92, 7021–7025.

42. Mellor, J.D., Brown, M.P., Irving, H.R., Zalcberg, J.R., Dobrovic, A., 2013. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J. Hematol. Oncol. 6, 1.

43. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., Royal, R.E., Topalian, S.L., Kammula, U.S., Restifo, N.P., Zheng, Z., Nahvi, A., de Vries, C.R., Rogers-Freezer, L.J., Mavroukakis, S.A., Rosenberg, S.A., 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129.

44. Muller, D., Kontermann, R.E., 2007. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr. Opin. Mol. Ther. 9, 319–326.

45. Nagorsen, D., Kufer, P., Baeuerle, P.A., Bargou, R., 2012. Blinatumomab: a historical perspective. Pharmacol. Ther. 136, 334–342.

46. Petersdorf, S.H., Kopecky, K.J., Slovak, M., Willman, C., Nevill, T., Brandwein, J., Larson, R.A., Erba, H.P., Stiff, P.J., Stuart, R.K., Walter, R.B., Tallman, M.S., Stenke, L., Appelbaum, F.R., 2013. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121, 4854–4860.

47. Raff, T., Gö kbuget, N., Luschen, S., Reutzel, R., Ritgen, M., Irmer, S., Bottcher, S., Horst, H.A., Kneba, M., Hoelzer, D., Brueggemann, M., 2007. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 109, 910–915.

48. Rosenblat, T.L., McDevitt, M.R., Mulford, D.A., Pandit-Taskar, N., Divgi, C.R., Panageas, K.S., Heaney, M.L., Chanel, S., Morgenstern, A., Sgouros, G., Larson, S.M., Scheinberg, D.A., Jurcic, J.G., 2010. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin. Cancer Res. 16, 5303–5311.

49. Schlegel, P., Lang, P., Zugmaier, G., Ebinger, M., Kreyenberg, H., Witte, K.E., Feucht, J., Pfeiffer, M., Teltschik, H.M., Kyzirakos, C., Feuchtinger, T., Handgretinger, R., 2014. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica 99, 1212–1219.

50. Schub, A., Nagele, V., Zugmaier, G., Brandl, C., Hijazi, Y., Topp, M.S., Kufer, P., Wolf, A., Klinger, M., 2013. Immunopharmacodynamic response to blinatumomab in patients with relapsed/ refractory B-precursor acute lymphoblastic leukemia (ALL). J. Clin. Oncol. 31, 7020 (abstract).

51. Staerz, U.D., Kanagawa, O., Bevan, M.J., 1985. Hybrid antibodies can target sites for attack by T cells. Nature 314, 628–631.

52. Stein, C., Kellner, C., Kugler, M., Reiff, N., Mentz, K., Schwenkert, M., Stockmeyer, B., Mackensen, A., Fey, G.H., 2010. Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br. J. Haematol. 148, 879–889.

53. Taussig, D.C., Pearce, D.J., Simpson, C., Rohatiner, A.Z., Lister, T.A., Kelly, G., Luongo, J.L., Danet-Desnoyers, G.A., Bonnet, D., 2005. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106, 4086–4092.

54. Teachey, D.T., Rheingold, S.R., Maude, S.L., Zugmaier, G., Barrett, D.M., Seif, A.E., Nichols, K.E., Suppa, E.K., Kalos, M., Berg, R.A., Fitzgerald, J.C., Aplenc, R., Gore, L., Grupp, S.A., 2013. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121, 5154–5157.

55. Topp, M.S., Gö kbuget, N., Stein, A.S., Zugmaier, G., O’Brien, S., Bargou, R.C., Dombret, H., Fielding, A.K., Heffner, L., Larson, R.A., Neumann, S., Foa, R., Litzow, M., Ribera, J., Rambaldi, A., Schiller, G., Bruggemann, M., Horst, H.A., Holland, C., Jia, C., Maniar, T., Huber, B., Nagorsen, D., Forman, S.J., Kantarjian, H.M., 2014. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 16, 57–66.

56. Topp, M.S., Gö kbuget, N., Zugmaier, G., Degenhardt, E., Goebeler, M.E., Klinger, M., Neumann, S.A., Horst, H.A., Raff, T., Viardot, A., Stelljes, M., Schaich, M., Kohne-Volland, R., Brueggemann, M., Ottmann, O.G., Burmeister, T., Baeuerle, P.A., Nagorsen, D., Schmidt, M., Einsele, H., Riethmuller, G., Kneba, M., Hoelzer, D., Kufer, P., Bargou, R.C., 2012. Long-term follow-up of hematological relapse-free survival in a phase 2 study of blinatumomab in patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (ALL). Blood 120, 5185–5187.

57. Topp, M.S., Kufer, P., Gö kbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.A., Raff, T., Viardot, A., Schmid, M., Stelljes, M., Schaich, M., Degenhard, E., Kohne- Volland, R., Bruggemann, M., Ottmann, O., Pfeifer, H., Burmeister, T., Nagorsen, D., Schmidt, M., Lutterbuese, R., Reinhardt, C., Baeuerle, P.A., Kneba, M., Einsele, H., Riethmuller, G., Hoelzer, D., Zugmaier, G., Bargou, R.C., 2011. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia￾free survival. J. Clin. Oncol. 29, 2493–2498.

58. Van der Velden, V.H., Corral, L., Valsecchi, M.G., Jansen, M.W., De Lorenzo, P., Cazzaniga, G., Panzer-Grumayer, E.R., Schrappe, M., Schrauder, A., Meyer, C., Marschalek, R., Nigro, L.L., Metzler, M., Basso, G., Mann, G., Den Boer, M.L., Biondi, A., Pieters, R., Van Dongen, J.J., Interfant-99 Study Group, 2009. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 23, 1073– 1079.

59. Walter, R.B., 2014. Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia. Expert Rev. Hematol. 7, 317–319.

60. Walter, R.B., Appelbaum, F.R., Estey, E.H., Bernstein, I.D., 2012. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 119, 6198–6208.

61. Whitlock, J., von Stackelberg, A., Handgretinger, R., Locatelli, F., Rizzari, C., Trippett, T.M., Borkhardt, A., O’Brien, M.M., Rheingold, S.R., Gore, L., 2014. Blinatumomab in pediatric patients with relapsed/refractory (r/r) B-cell precursor acute lym phoblastic leukemia (BCP-ALL): a phase 1/2 study. Int. Soc. Paediatric Oncol. Annu. Congr.


Для цитирования:


Зугмайер Г., Клингер М., Шмидт М., Субклеве М., Киргизов К.И., Шаманская Т.В. Клинический обзор анти-CD19 BiTE® и ex vivo данных об анти-CD33 BiTE® в качестве примеров ретаргетирования Т-клеток при гематологических опухолях. Российский журнал детской гематологии и онкологии (РЖДГиО). 2016;3(2):18-30. https://doi.org/10.17650/2311-1267-2016-3-2-18-30

For citation:


Zugmaier G., Klinger M., Schmidt M., Subklewe M., Kirgizov K.I., Shamanskaya T.V. Clinical overview of anti-CD19 BiTE® and ex vivo data from anti-CD33 BiTE® as examples for retargeting T cells in hematologic malignancies. Russian Journal of Pediatric Hematology and Oncology. 2016;3(2):18-30. (In Russ.) https://doi.org/10.17650/2311-1267-2016-3-2-18-30

Просмотров: 219


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2311-1267 (Print)
ISSN 2413-5496 (Online)